You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Moodys
Boehringer Ingelheim
McKinsey
Harvard Business School

Last Updated: March 29, 2020

DrugPatentWatch Database Preview

XENICAL Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Xenical patents expire, and what generic alternatives are available?

Xenical is a drug marketed by Cheplapharm and is included in one NDA.

The generic ingredient in XENICAL is orlistat. There are twelve drug master file entries for this compound. Additional details are available on the orlistat profile page.

Drug patent expirations by year for XENICAL
Drug Prices for XENICAL

See drug prices for XENICAL

Recent Clinical Trials for XENICAL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Pennington Biomedical Research CenterN/A
GlaxoSmithKlineN/A
Germed PharmaN/A

See all XENICAL clinical trials

Synonyms for XENICAL
(-)-tetrahydrolipostatin
(-)-Tetrahydrolipstatin
(-)-Tetrahydrolipstatin; N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl] dodecyl ester; Ro-18-0647
(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl (2S)-2-formamido-4-methylpentanoate
(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl N-formyl-L-leucinate
(2S)-2-formamido-4-methylpentanoic acid [(2S)-1-[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]tridecan-2-yl] ester
(S)-((S)-1-((2S,3S)-3-hexyl-4-oxooxetan-2-yl)tridecan-2-yl) 2-formamido-4-methylpentanoate
(S)-1-((2S,3S)-3-hexyl-4-oxooxetan-2-yl)tridecan-2-yl formyl-L-leucinate
[(1S)-1-[[(2S,3S)-3-hexyl-4-oxo-oxetan-2-yl]methyl]dodecyl] (2S)-2-formamido-4-methyl-pentanoate
[(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate
2-formamido-3-[(3-hexyl-4-oxo-oxetan-2-yl)methyl]-2-isobutyl-tetradecanoate
829O582
95M8R751W8
96829-58-2
AB00639987_10
AB00639987-09
AB1009256
AHLBNYSZXLDEJQ-FWEHEUNISA-N
AKOS015894875
Alli
AOB6737
BCP0726000044
BCP9001031
BDBM24567
BIDD:GT0853
C29H53NO5
CCG-100851
CHEBI:94686
CHEMBL175247
CPD000466339
CS-2165
D04028
DB01083
DTXSID8023395
FT-0082584
FT-0601570
GTPL5277
HMS2051I08
HMS3413P06
HMS3677P06
HSDB 7556
HY-B0218
J90006
KS-1183
L-Leucine, N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester
L-Leucine, N-formyl-, (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester
L-Leucine, N-formyl-, 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester, (2S-(2alpha(R*),3beta))-
L-Leucine,N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester
LEU002
LS-178328
MFCD05662360
MLS000759448
MLS001423955
MLS002207022
N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester
N-formyl-L-leucine (1S)-1-{[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl}dodecyl ester
N-formyl-L-leucine (S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester
N-formyl-L-leucine-(S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]-dodecyl ester
N-Formyl-L-leucine, ester with (3S,4S)-3-hexyl-4-((2S)-2-hydroxytridecyl)-2-oxetanone
NC00101
NCGC00165856-01
NCGC00165856-02
O0381
Orlipastat
Orlipastatum
Orlipastatum [INN-Latin]
orlistat
Orlistat (Alli, Xenical)
Orlistat (JAN/USAN/INN)
Orlistat [USAN:INN:BAN]
Orlistat [USAN:INN]
Orlistat, >=98%, solid
Orlistat, Pharmaceutical Secondary Standard; Certified Reference Material
Orlistat, United States Pharmacopeia (USP) Reference Standard
Orlistat,Tetrahydolipstat
Orlistat(Alli)
orlistatum
PubChem18271
Q-201519
Q424163
R-212
Ro 18-0647
Ro 18-0647/002
Ro 18-0647/008
Ro-18-0647
Ro-18-0647/002
Ro-180647-002
Ro-180647002
s1629
SAM001246637
SC-16265
SCHEMBL16408
SMR000466339
SR-01000759417
SR-01000759417-5
SR-01000759417-7
ST24048848
SW197481-2
tetrahydrolipastatin
Tetrahydrolipstatin
Tetrahydrolipstatin;Ro-18-0647
Tetrahydrolipstatin|||Ro 18-0647/002
THL
THLP
UNII-95M8R751W8
Xenical (TN)
Z2379810072
ZINC8214635
ZLA0015
zlchem 13

US Patents and Regulatory Information for XENICAL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cheplapharm XENICAL orlistat CAPSULE;ORAL 020766-001 Apr 23, 1999 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for XENICAL

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0129748 SPC/GB98/044 United Kingdom   Start Trial PRODUCT NAME: ORLISTAT; REGISTERED: UK EU/1/98/071/001 19980729; UK EU/1/98/071/002 19980729; UK EU/1/98/071/003 19980729; UK EO/1/98/071/004 19980729; UK EU/1/98/071/005 19980729; UK EU/1/98/071/006 19980729
0129748 98C0042 Belgium   Start Trial PRODUCT NAME: ORLISTAT; REGISTRATION NO/DATE: EU/1/98/071/001 19980729
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Moodys
Boehringer Ingelheim
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.